Reuters logo
BRIEF-Erytech presents new preclinical data supporting ERY-MET
January 18, 2017 / 7:15 AM / 10 months ago

BRIEF-Erytech presents new preclinical data supporting ERY-MET

Jan 18 (Reuters) - Erytech Pharma SA :

* Reported on Tuesday findings from preclinical studies demonstrate that ERY-MET, which is methionine gamma-lyase-encapsulated in red blood cells (RBC) developed using co’s proprietary ERYCAPS encapsulation platform technology, can inhibit tumor growth in a murine model of human gastric adenocarcinoma; this effect can be regulated by Vitamin B6 supplementation

* Methionine gamma-lyase-encapsulated into red blood cells (ERY-MET) shows profound antitumor activity in gastric carcinoma

* Study found that ERY-MET, in combination with daily Vitamin B6 supplementation, increased active MGL half-life in vivo, from less than 24 hours to 8-9 days.

* Combined ERY-MET and Vitamin B6 treatment exhibited anti-tumor activity in 100 pct of treated mice, with tumor growth inhibitions varying from 91 pct to 100 pct by the end of the study

Source text for Eikon: Further company coverage:

Gdynia Newsroom

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below